Siegfried Holding AG
SFZN
Rang in aandelen
#4106
Siegfried Holding AG, together with its subsidiaries, engages in contract... Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Aandeelprijs
$88.34
Marktkapitalisatie
$3.87B
Verandering (1 dag)
1.68%
Verandering (1 jaar)
-12.97%
Land
CH
Handel Siegfried Holding AG (SFZN)
Categorie
Healthcare
P/B-ratio voor Siegfried Holding AG (SFZN)
P/B-ratio op October 2026 TTM: 3.21
Volgens de meest recente financiële rapporten en aandelenkoers van Siegfried Holding AG is de huidige P/B-ratio (TTM) 3.21. Eind 2024 had het bedrijf een P/B-ratio van 4.34.
P/B-ratiohistoriek voor Siegfried Holding AG van 2002 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 3.21 | 11.16% |
| 2025 | 2.89 | -33.25% |
| 2024 | 4.34 | -0.24% |
| 2023 | 4.35 | 19.29% |
| 2022 | 3.64 | -40.77% |
| 2021 | 6.15 | 12.88% |
| 2020 | 5.45 | 22.37% |
| 2019 | 4.45 | 120.61% |
| 2018 | 2.02 | 4.80% |
| 2017 | 1.93 | 53.74% |
| 2016 | 1.25 | -20.24% |
| 2015 | 1.57 | -4.07% |
| 2014 | 1.64 | -6.38% |
| 2013 | 1.75 | 35.03% |
| 2012 | 1.30 | 45.24% |
| 2011 | 0.89 | 8.97% |
| 2010 | 0.82 | 3.87% |
| 2009 | 0.79 | 9.98% |
| 2008 | 0.72 | -35.56% |
| 2007 | 1.11 | -1.79% |
| 2006 | 1.13 | 8.00% |
| 2005 | 1.05 | 6.17% |
| 2004 | 0.99 | -7.37% |
| 2003 | 1.07 | -6.84% |
| 2002 | 1.14 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 1.9834 | -38.26% |
DE
|
|
| 2.1139 | -34.20% |
DE
|
|
| 1.3124 | -59.15% |
JP
|
|
| 6.3468 | 97.56% |
CH
|
|
| 5.0287 | 56.53% |
IN
|
